Parameter
| Biomarker | APOE ε4 | Full name | Apolipoprotein E ε4 | Molecular Type | Nucleic Acid (DNA) |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Susceptibility |
| Disease | Alzheimer's Disease | Disease Subtypes | / | ||
| Organ | Brain | Test Sample / Technology Platform | Whole Blood (Genotyping) | ||
| Pathobiological Mechanisms | Affects lipid metabolism, particularly associated with reduced Aβ clearance efficiency; carriers have an increased risk and earlier timing of Aβ deposition. | ||||
| Clinical Availability Status | Clinically available (risk assessment): Routine genetic testing is available, but only for risk assessment, not diagnosis. Involves important ethical issues. | ||||
| Notes and Dynamics | A core variable for establishing risk stratification models; also an important stratification factor in therapeutic trials. | ||||